Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab + Chemotherapy for Newly Diagnosed BCR-ABL-Negative B Lineage ALL in Adults
NCT02003222Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2014
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started May 2014; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02003222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02003222.